argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating PolyneuropathyGlobeNewsWire • 12/27/24
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory MyopathiesGlobeNewsWire • 11/20/24
Steritas Announces Collaboration with argenx to Advance Evidence for Novel Steroid-sparing TherapeuticsBusiness Wire • 11/19/24
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in ChinaGlobeNewsWire • 11/11/24
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in ChinaBusiness Wire • 11/11/24
argenx Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 10/31/24
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024GlobeNewsWire • 10/24/24
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific SessionsGlobeNewsWire • 10/15/24
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune DiseasesInvestors Business Daily • 09/25/24
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating PolyneuropathyGlobeNewsWire • 09/19/24
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business UpdateGlobeNewsWire • 07/25/24